CGTLive’s Weekly Rewind – August 11, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Lifileucel's Phase 3 TILVANCE-301 Trial Kicks Off in Patients With Melanoma

The TIL therapy has a PDUFA date of November 25, 2023.

2. Brian Van Tine, MD, PhD, on Progress and Challenges With Cell Therapy for Sarcoma

The professor of medicine and pediatrics at Washington University in St. Louis discussed the current investigative landscape for cell therapy in treating sarcomas.

3. MUC16-Targeted Bispecific T-Cell Engager Cleared for Trial in Ovarian Cancer, Other Tumors

The first participant was dosed with LBL-033 in April 2023 in Nanjing Lead Biolabs's ongoing trial in China.

4. J. Andrew Livingston, MD, on Potential Advantages of TCR NK Therapy for Synovial Sarcoma and MRCL

The associate professor at MD Anderson Cancer Center discussed challenges with developing cell therapy for sarcoma and how TCR NK therapy's unique characteristics may prove useful.

5. AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy Trial Doses First Patient

LION-CS101, the study evaluating gene therapy AB-1003, is currently recruiting patients aged 18 years through 65 years with LGMD2I/R9 who have a confirmed mutation in FKRP.